LES PUBLICATIONS. Belouzard S. Mécanismes d entrée des coronavirus. Virologie, 2010, 14:1-15.

Size: px
Start display at page:

Download "LES PUBLICATIONS. Belouzard S. Mécanismes d entrée des coronavirus. Virologie, 2010, 14:1-15."


1 LES PUBLICATIONS MOLECULAR AND CELLULAR VIROLOGY OF HEPATITIS Inserm U CNRS UMR 8204 University Lille 1 - University Lille 2 Institut Pasteur de Lille affiliated to IFR 142 Responsable Jean DUBUISSON Ahmed-Belkacem A, Ahnou N, Barbotte L, Wychowski C, Pallier C, Brillet R, Pohl RT, Pawlotsky JM. Silibinin and related compounds are direct inhibitors of hepatitis C virus RNA-dependent RNA polymerase. Gastroenterology, 2010, 38: Belouzard S. Mécanismes d entrée des coronavirus. Virologie, 2010, 14:1-15. Belouzard S, Madu I, Whittaker GR. Elastase activation of the SARS coronavirus spike protein at discrete sites within S2 domain. J Biol Chem, 285: Ciczora I, Callens N, Séron K, Rouillé Y, Dubuisson J. Identification of a dominant endoplasmic reticulum retention signal in yellow fever virus pre-membrane protein. J Gen Virol, 2010, 91: Goueslain L, Alsaleh K, Horrelou P, Roingeard P, Descamps V, Duverlie G, Ciczora Y, Wychowski C, Dubuisson J, and Rouillé Y. Identification of GBF1 as a cellular factor required for HCV RNA replication. J Virol, 2010, 84: Helle F, Vieyres G, Elkrief L, Popescu I, Wychowski C, Descamps V, Castelain S, Duverlie G, Dubuisson J. Role of N-linked glycans in the functions of HCV envelope proteins incorporated into infectious virions. J Virol, 2010, in press. Montserret R, Saint N, Vanbelle C, Salvay A, Simorre JP, Ebel C, Sapay N, Renisio JG, Böckmann A, Steinmann E, Pietschmann T, Dubuisson J, Chipot C, Penin F. NMR structure analysis and ion channel activity of the p7 polypeptide from hepatitis C virus. J Biol Chem, 2010, in press. Pawlotsky JM, Cocquerel L, Durantel D, Lavillette D, Lerat H, Pécheur EI, Polyak SJ, Tautz N, Thimme R. HCV research 20 years after discovery : a summary of the 16th international meeting on hepatitis c virus and related viruses. Gastroenterology, 2010, 138:6-12. Popescu CI, Dubuisson J. Role of lipid metabolism in hepatitis C virus assembly and entry. Biol Cell, 2010, 102: Tews B, Popescu CI, Dubuisson J. Last stop before exit Hepatitis C assembly and release as antiviral drug targets. Viruses, 2010, 2: Vieyres G, Thomas X, Descamps V, Duverlie G, Patel AH, Dubuisson J. Characterization of the envelope glycoproteins associated with infectious hepatitis C virus. J Virol, 2010, 84:

2 2009 Alvarez-Lajonchere L, Shoukry N, Gra B, Amado-Canizares Y, Helle F, Bedard N, Guerra I, Drouin C, Dubuisson J, Gonzalez Horta EE, Martinez G, Marante J, Cinza Z, Castellanos M, Duenas-Carrera S. Immunogenicity of CIGB-230, a therapeutic DNA vaccine preparation, in HCV-chronically infected individuals in a phase I clinical trial. J Viral Hepatitis, 2009, 16: Charrin S, Yalaoui S, Bartosch B, Cocquerel L, Franetich JF, BoucheixC, Mazier D, Rubinstein E, Silvie O. The IG domain protein CD9P-1 down-regulates CD81 ability to support plasmodium YOELII infection. J Biol Chem, 2009, 284: Dubois A, Francois C, Descamps V, Fournier C, Wychowski C, Dubuisson J, Castelain S, Duverlie G. Enhanced anti-hcv activity of interferon alpha 17 subtype. Virol J, 2009, 6:70. Helle F, Dubuisson J. Rôle des N-glycanes dans les fonctions des protéines d enveloppe du virus de l hépatite C. Virologie, 2009, 13: Kuzmina TI, Olenina LV, Sanzhakov MA, Farafonova TE, Abramihina TV, Dubuisson J, Sobolev BN, Kolesanova EF. Antigenicity and B-epitope mapping of hepatitis C virus envelope protein E2. Biomed Chem (Moscow), 2009, 55: Rocha-Perugini V, Lavie M, Delgrange D, Canton J, Pillez A, Potel J, Lecoeur C, Rubinstein E, Dubuisson J, Wychowski C, Cocquerel L. The association of CD81 with tetraspanin-enriched microdomains is not essential for Hepatitis C Virus entry. BMC Microbiol, 2009, 9:111. Roohvand F, Maillard P, Lavergne JP, Boulant S, Walic M, Andréo U, Goueslain L, Helle F, McLauchlan J, Budkowska A. Initiation of hepatitis C virus infection requires the dynamic microtubule network: Role of the viral nucleocapsid protein. J Biol Chem, 2009, 284: Tews BA, Cocquerel L. Occludin, an additional key for hepatitis C virus entry. Med Sci (Paris), 2009, 25: Tews BA, Dubuisson J. Occludin, the final essential factor for HCV entry? Future Virology, 2009, 4: Touvier T, Conte-Auriol F, Briand O, Cudejko C, Paumelle R, Caron S, Baugé E, Rouillé Y, Salles JP, Staels B, Bailleul B. LEPROT and LEPROTL1 cooperatively decrease hepatic growth hormone action in mice. J Clin Invest, 2009, 119 : Vieyres G, Angus AG, Haberstroh A, Baumert TF, Dubuisson J, Patel AH. Rapid synchronization of hepatitis C virus infection by magnetic adsorption. J Virol Methods, 2009, 157(1): Castelain S, Schnuriger A, François C, Nguyen-Khac E, Fournier C, Schmit JL, Capron D, Dubuisson J, Wychowski C, Thibault V, Duverlie G. Lower levels of HCV neutralizing antibodies in HIV/HCV-coinfected patients than in HCV-monoinfected patients. J Infect Dis, 2008, 198 : Dubuisson J, Helle F, Cocquerel L. Early steps of the Hepatitis C Virus life cycle. Cell Microbiol, 2008, 10:

3 Helle F, Dubuisson J. Hepatitis C Virus entry into host cells. Cell Mol Life Sci, 2008, 65: Helle F, Dubuisson J. Mechanism and inhibition of Hepatitis C Virus entry. J Viral Entry, 2008, 3: Helle F, Cocquerel L. L entrée du virus de l hépatite C dans ses cellules cibles. Virologie, 2008, 12: Jaffrelo L, Chabas S, Reigadas S, Pflieger A, Wychowski C, Rumi J, Ventura M, Toulmé JJ, Staedel C. A functional selection of viral genetic elements in cultured cells to identify hepatitis C virus RNA translation inhibitors. Nucleic Acids Res, 2008, 36:e95. Machida K, Kondo Y, Huang J, Chen YC, Cheng KTH, Keck Z, Foung S, Dubuisson J, Sung VMH, Lai MMC. HCV-induced Immunoglobulin Hypermutation Reduces the Affinity and Neutralizing Activities of Antibodies against HCV Envelope Protein. J Virol, 2008, 82: Molina S, Castet V, Pichard-Garcia L, Wychowski C, Meurs E, Pascussi JM, Sureau C, Fabre JM, SaCunha A, Larrey D, Dubuisson J, Coste J, McKeating J, Maurel P, Fournier-Wirth C. Serum derived HCV infection of primary human hepatocytes is tetraspanin CD81 dependent. J Virol, 2008, 82: Rocha-Perugini V, Montpellier C, Delgrange D, Wychowski C, Helle F, Pillez A, Drobecq H, Le Naour F, Charrin S, Levy S, Rubinstein E, Dubuisson J, Cocquerel L. The CD81 partner EWI-2wint inhibits hepatitis C virus entry. PLoS ONE 3, 2008, e1866. Voisset C, Lavie M, Helle F, Op De Beeck A, Bilheu A, Bertrand-Michel J, Tercé F, Cocquerel L, Wychowski C, Vu-Dac N, Dubuisson J. Ceramide enrichment of the plasma membrane induces CD81 internalization and inhibits HCV entry. Cell Microbiol, 2008, 10: Voisset C, Weiss RA, Griffiths DJ. Human RNA "rumor" viruses : the search for novel human retroviruses in chronic disease. Microbiol Mol Biol Rev, 2008, 72: Antoine AF, Montpellier C, Cailliau K, Browaeys-Poly E, Vilain JP, Dubuisson J. The Alphavirus 6K protein activates endogenous ionic conductances when expressed in Xenopus oocytes. J Membr Biol, 2007, 215: Akazawa D, Date T, Morikawa K, Murayama A, Miyamoto M, Kaga M, Barth H,. Baumert T, Dubuisson J, Wakita T. CD81 expression is important for heterogeneous HCV permissiveness of Huh7 cell clones. J Virol, 2007, 81, Brochot E, Duverlie G, Castelain S, Morel V, Wychowski C, Dubuisson J, François C. Effect of ribavirin on the hepatitis C virus (JFH-1) and its correlation with interferon sensitivity. Antivir Ther, 2007, 12: Castelain S, Bonte D, Penin F, Francois C, Capron D, Dedeurwaerder S, Zawadzki P, Morel V, Wychowski C, Duverlie G. Hepatitis C Virus p7 membrane protein quasispecies variability in chronically infected patients treated with interferon and ribavirin, with or without amantadine. J Med Virol, 2007, 79:

4 Chapel C, Garcia C, Bartosh B, Roingeard P, Zitzmann N, Cosset FL, Dubuisson J, Dwek RA, Trépo C, Zoulim F, Durantel D. Reduction of the infectivity of hepatitis C virus pseudoparticles by incorporation of misfolded glycoproteins induced by glucosidase inhibitors. J Gen Virol, 2007, 88: Chevalier C, Saulnier A, Benureau Y, Flechet D, Delgrange D, Colbere-Garapin F, Wychowski C, Martin A. Inhibition of Hepatitis C Virus Infection in Cell Culture by Small Interfering RNAs. Mol Ther, 2007, 15: Ciczora Y, Callens N, Penin F, Pécheur EI, Dubuisson J. The transmembrane domains of HCV envelope glycoproteins: residues involved in E1E2 heterodimerization and involvement of these domains in virus entry. J Virol, 2007, 81: Couturier C, Sarkis C, Séron K, Belouzard S, Chen P, Lenain A, Corset L, Dam J, Vauthier V, Dubart A, Mallet J, Froguel P, Rouillé Y, Jockers R. Silencing of OB-RGRP in mouse hypothalamic arcuate nucleus increases leptin receptor signaling and prevents dietinduced obesity. Proc Natl Acad Sci USA, 2007, 104: Delgrange D, Pillez A, Castelain S, Cocquerel L, Rouillé Y, Dubuisson J, Wakita T, Duverlie G, Wychowski C. Robust production of infectious viral particles in Huh-7 cells by introducing mutations in hepatitis C virus structural proteins. Gen Virol, 2007, 88: Dubuisson J. Hepatitis C virus proteins. World J Gastroenterol, 2007, 13: Duverlie G, Wychowski C. Cell culture systems for the hepatitis C virus. World J Gastroenterol, 2007, 13: Fournier C, Duverlie G, Francois C, Schnuriger A, Dedeurwaerder S, Brochot E, Capron D, Wychowski C, Thibault V, Castelain S. A focus reduction neutralization assay for hepatitis C virus neutralizing antibodies. Virol J, 2007, 4:35. Gatignol A, Dubuisson J, Wainberg MA, Cohen EA, Jean-Luc Darlix JL. New pandemics: HIV and AIDS, HCV and chronic hepatitis, Influenza virus and flu. Retrovirology, 2007, 4:8. Helle F, Goffard A, Morel V, Duverlie G, McKeating J, Keck ZY, Foung S, Penin F, Dubuisson J, Voisset C. The neutralizing activity of anti-hcv antibodies is modulated by specific glycans on the E2 envelope protein. J Virol, 2007, 81: Johansson DX, Voisset C, Tarr AW, Aung M, Ball JK, Dubuison J, Persson M. Human combinatorial libraries yield rare antibodies that broadly neutralize hepatitis C virus. Proc Natl. Acad Sci USA, 2007, 104: Lavie M, Goffard A, Dubuisson J. Assembly of a functional HCV glycoprotein heterodimer. Curr Issues Mol Biol, 2007, 9: PhD François HELLE Directeur de thèse : J Dubuisson "Les N-glycanes du Virus de l'hépatite C protègent contre la neutralisation mais sont une cible thérapeutique potentielle" 27 septembre 2007

5 David DELGRANGE Directeur de thèse : C Wychowski "Etude de la multiplication de la souche JFH-1 du virus de l hépatite C (VHC) en cellules Huh-7. Adaptation et sélection de mutations permettant une production rapide et massive du VHC. Localisation subcellulaire de protéines du VHC. Mise en évidence de clones cellulaires résistants à l infection par le VHC" 21 septembre 2007 Vera ROCHA Directeur de thèse : L Cocquerel "Identification d EWI-2wint, un partenaire de CD81 qui inhibie l entrée du VHC" 26 septembre 2007 HDR Ngoc VU-DAC "Rôle des lipoprotéines, transfert lipidique et mécanismes d entrée du VHC dans les hépatocytes" Laurence COQUEREL "Identification et caractérisation d'un inhibiteur de l entrée du virus de l'hépatite C" Karin SERON "Etude de différents aspects du trafic membranaire : de la levure Saccharomyces cerevisiae à l'obésité humaine"